سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Razzaghdoust, Abolfazl, Muhammadnejad, Samad, Parvin, Mahmoud, Mofid, Bahram, Zangeneh, Masoumeh, Basiri, Abbas. (1400). Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer. , 24(12), 1650-1655. doi: 10.22038/ijbms.2021.59943.13305
Abolfazl Razzaghdoust; Samad Muhammadnejad; Mahmoud Parvin; Bahram Mofid; Masoumeh Zangeneh; Abbas Basiri. "Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer". , 24, 12, 1400, 1650-1655. doi: 10.22038/ijbms.2021.59943.13305
Razzaghdoust, Abolfazl, Muhammadnejad, Samad, Parvin, Mahmoud, Mofid, Bahram, Zangeneh, Masoumeh, Basiri, Abbas. (1400). 'Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer', , 24(12), pp. 1650-1655. doi: 10.22038/ijbms.2021.59943.13305
Razzaghdoust, Abolfazl, Muhammadnejad, Samad, Parvin, Mahmoud, Mofid, Bahram, Zangeneh, Masoumeh, Basiri, Abbas. Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer. , 1400; 24(12): 1650-1655. doi: 10.22038/ijbms.2021.59943.13305

Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer

Iranian Journal of Basic Medical Sciences
مقاله 5، دوره 24، شماره 12، اسفند 2021، صفحه 1650-1655    اصل مقاله (819.82 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2021.59943.13305
نویسندگان
Abolfazl Razzaghdoust1؛ Samad Muhammadnejad2؛ Mahmoud Parvin3؛ Bahram Mofid4؛ Masoumeh Zangeneh5؛ Abbas Basiri* 1
1Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Gene Therapy Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3Department of Pathology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Oncology, Shohada-e-Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Objective(s): Patient-derived xenograft (PDX) models have become a valuable tool to evaluate chemotherapeutics and investigate personalized cancer treatment options. The role of PDXs in the study of bladder cancer, especially for improvement of novel targeted therapies, continues to expand. In this study, we aimed to establish autochthonous PDX models of muscle-invasive bladder cancer (MIBC) to provide a useful tool to conduct research on personalized therapy. 
Materials and Methods: Tumors from MIBC patients undergoing radical cystectomy were subcutaneously transplanted into immunodeficient mice. The tumor size was measured by a caliper twice a week for up to five months. After the first growth in mice, they were serially passaged. Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) of 11 markers (Ki67, P63, GATA3, KRT5/6, KRT20, E-cadherin, 34βE12, PD-L1, EGFR, Nectin4, and HER2) were used to evaluate phenotype maintenance of original tumors.
Results: From 10 MIBC patients, two PDX models (P8X20 and P8X26) were successfully established (20% success rate). These models mostly retained primary tumor characteristics including histology, morphology, and molecular nature of the original cancer tissues. IHC analysis showed that the expression level of 7 markers for the model P8X20, and 8 markers for the model P8X26 was exactly similar between the patient tumor and the next generations.
Conclusion: We developed the first autochthonous PDX models of MIBC in Iran. Our data suggested that the established MIBC PDX models reserved mostly histopathological characteristics of primary cancer and could provide a new tool to evaluate novel biomarkers, therapeutic targets, and drug combinations.
کلیدواژه‌ها
Animal model؛ Chemotherapy؛ Muscle-invasive bladder cancer؛ Patient-derived xenograft؛ Targeted therapy
سایر فایل های مرتبط با مقاله
مراجع
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209-249.
2. Berdik C. Unlocking bladder cancer. Nature 2017; 551:S34-s35.
3. Suprynowicz FA, Upadhyay G, Krawczyk E, Kramer SC, Hebert JD, Liu X, et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 2012; 109:20035-20040.
4. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
5. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9:338-350.
6. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Löhr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984:343-352.
7. Shorthouse AJ, Smyth JF, Steel GG, Ellison M, Mills J, Peckham MJ. The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg 1980; 67:715-722.
8. Suh YS, Jeong K-C, Lee S-J, Seo HK. Establishment and application of bladder cancer patient-derived xenografts as a novel preclinical platform. Transl Cancer Res 2017:S733-S743.
9. Williams JA. Using PDX for preclinical cancer drug discovery: The evolving field. J Clin Med 2018; 7.
10. Bernardo C, Costa C, Sousa N, Amado F, Santos L. Patient-derived bladder cancer xenografts: a systematic review. Transl Res 2015; 166:324-331.
11. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100:3175-3182.
12. Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol 2015; 47:61-70.
13. Paez-Ribes M, Man S, Xu P, Kerbel RS. Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: A cautionary note. PLoS One 2016; 11:e0158034.
14. Razzaghdoust A, Ghajari M, Basiri A, Mohammadi Torbati P, Jafari A, Fattahi MR, et al. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer. Investig Clin Urol 2021; 62: 274-281.
15. Simon R. Tissue microarrays: methods and protocols: Wiley Online Library; 2010.
16. Mondal AM, Ma AH, Li G, Krawczyk E, Yuan R, Lu J, et al. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun 2019; 517:49-56.
17. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 2015; 6:21522-21532.
18. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, et al. Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. PLoS One 2015; 10:e0134346.
19. Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 2013; 104:631-638.
20. Bernardo C, Santos LL. Patient-derived bladder cancer xenografts. Methods Mol Biol 2018; 1655:169-175.
21. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4:1670-1680.

آمار
تعداد مشاهده مقاله: 876
تعداد دریافت فایل اصل مقاله: 600